From Nasdaq:

GSK has acquired private biotech company Aiolos, which makes medicines for respiratory and inflammatory conditions. The acquisition will strengthen GSK’s respiratory biologics pipeline with Aiolos’ lead pipeline candidate, AIO-001, a long-acting antibody targeting the TSLP pathway. GSK has seen a 14.5% stock increase in the past year and currently holds a Zacks Rank #3 (Hold).

GSK will make an upfront payment of $1 billion for the acquisition, with Aiolos potentially receiving $400 million in regulatory milestone payments. Adding AIO-001 to GSK’s portfolio can help reach a broader population of asthma patients, and it has potential to redefine the standard of care by offering a longer dosing interval. AIO-001 was acquired by Aiolos outside of China from Jiangsu Hengrui Pharmaceuticals.

For the past 60 days, estimates for Regeneron’s 2024 earnings per share have increased to $43.66, with the stock rising 29.1% in the past year. Regeneron has beaten estimates in the last four quarters, delivering an average earnings surprise of 12.34%. Sarepta’s 2024 earnings per share estimates have increased to $1.72, and Puma Biotechnology’s estimates have risen to $0.69. Both companies have seen stock increases, with Sarepta beating estimates in the last four quarters and Puma Biotechnology in three out of the last four quarters.

Experts have identified seven elite stocks from the current list of 220 Zacks Rank #1 Strong Buys, including Regeneron Pharmaceuticals, Sarepta Therapeutics, and Puma Biotechnology. The full list has beaten the market more than 2X over, with an average gain of +24.0% per year. These hand-picked stocks are considered the “Most Likely for Early Price Pops.”

See them now >>



Read more: GSK to Buy Private Biotech, Strengthen Respiratory Pipeline